spacer
home > ict > winter 2008 > research reaches beyond borders
PUBLICATIONS
International Clinical Trials

Research Reaches Beyond Borders

As the growth of clinical research market activity continues, Irina Dobreva of Congenix LLC evaluates Russia and Ukraine’s role in international clinical trials in 2007, and asks what 2008 has in store

Clinical research currently is a highly relevant issue in Russia. Having started its development in the late 1980s, this area of medical activity is now stable and not expected to be subject to drastic reform, as it is based on robust legislation. Russia has by now become internationally acknowledged in the field of clinical research, thanks to the highly qualified physicians and the technical capabilities that promote rapid patient recruitment into clinical trials.

Nevertheless, close monitoring of the clinical research market in Russia highlights the ban on exporting biological samples that ran for two weeks in June 2007 and jeopardised trials conducted there. Those two ‘black’ weeks have undoubtedly had a negative impact on Russia’s rating, although that impact was a short-term one. For instance, according to information from the Russian Ministry of Health, the number of international multicentre clinical trials in Q2 2007 was reduced by 22 per cent when compared with Q2 2006.

However, as early as Q3 2007, the clinical trial market stabilised and 92 clinical trials were permitted by Roszdravnadzor (the public health and social development watchdog agency) to take place in Russia versus 95 in Q3 of the previous years. The total number of international multicentre clinical trials approved in Russia in Q1-3 in 2007 was 236. The distribution of clinical trials in groups of priority indications and phases is presented in Table 1 (1).

In 2007 GlaxoSmithKline, Sanofi-Aventis, AstraZeneca, Hoffmann-La Roche and Bristol-Myers Squibb became frontrunners in Russia in terms of the number of trials, the total number of study sites involved in trials and the total number of patients expected to be randomised (2). As predicted, the quantity of patients falls when related to clinical trials in cardiovascular disease (see Figure 1). The most active therapeutic areas in the number of trials are oncology and endocrinology (see Figure 2).

THE FORMATION OF THE REGULATORY SYSTEM AND ETHICS EXPERTISE IN UKRAINE

The legal procedures for conducting clinical trials in Ukraine are set by the state law ‘On medicinal products’ (1996), which governs how trials should be conducted, and the typical regulations for ethics commissions, approved by the Ukrainian Ministry of Health in 2006. The development of the latter documents took into consideration the requirements of Directive 2001/20/EC (3).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Irina Dobreva is Chief Executive Officer and co-founder of Congenix LLC, a Russian CRO established in 2004. Irina has extensive experience in clinical trials, not least starting as an expert at the Russian Ministry of Health. Before founding Congenix, Irina was involved in the implementation of several oncology studies in numerous Russian investigational sites for an American CRO. She qualified in Medicine from Ural State Medical University and trained in Oncology. Irina undertook PhD research at Russia’s biggest oncology research centre specialising in breast cancer treatment.
spacer
Irina Dobreva
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Mr Turhan Ozen Chief Cargo Officer at Turkish Airlines elected to the International Air Cargo Association (TIACA) Committee

Turhan Ozen, serving as Chief Cargo Officer at the global brand Turkish Airlines, was elected to the International Air Cargo Association (TIACA) Committee, the joint voice of the industry that aims to enhance the air cargo profile with intensive efforts towards the global standards.
More info >>

White Papers

Shipping with Active Packaging Containers: Three Pre-flight Decisions that Impact the Success of High-value Global Shipments

World Courier

It is the dead of winter in the northern hemisphere and the height of summer in the southern, with external temperature fluctuations exceeding 50 degrees. Flight delays have added precious days to the transport of your multi-million dollar shipment of blockbuster drug from South East Asia destined for Russia. In France, the roads are closed for days due to a monster snowstorm, with your irreplaceable shipment of investigational drugs stopped somewhere en route between Paris and the clinical trial site. Will all be lost, or can informed choices made before the shipment departs ensure product safety despite unforeseen circumstances?
More info >>

 
Industry Events

Clinical Trial Supply Global Forum

20-22 May 2019, Brussels, Belgium

You can’t get a drug to market without a clinical trial. You can’t run a clinical trial without product supply. We understand that your role is critical in ensuring the on time and efficient development of the next life saving drug and we know that this makes your time precious. In 2019 we have condensed everything you need to advance your Clinical Trial Supply into three jam packed days. The industry's most interactive and solution focused CTS forum features deep dive workshops, live polls, panel debates, round table discussions and exclusive key note case studies to ensure that you leave with the industry's best solutions and strategies to transform your clinical trial supply. If there is ONE Clinical Trial Supply conference that you attend in 2019, make sure that it is this one.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement